Halozyme Therapeutics reported third-quarter 2026 total revenue of $493 million, a 39% increase year-over-year, driven by royalty growth and product sales. The company raised its full-year 2026 financial guidance, projecting total revenue between $1.86 billion and $1.925 billion, non-GAAP diluted EPS of $8.75 to $9.05, and adjusted EBITDA of $1.24 billion to $1.29 billion. The firm also announced the expansion of collaboration agreements with partners including argenx, Incyte, and Johnson & Johnson for its ENHANZE drug delivery technology. Halozyme Therapeutics is a biopharmaceutical company specializing in subcutaneous drug delivery technologies.
